Aerosolized bovine lactoferrin reduces lung injury and fibrosis in mice exposed to hyperoxia.
This study investigated the ability of aerosolized bovine lactoferrin (bLF) to protect the lungs from injury induced by chronic hyperoxia. Female CD-1 mice were exposed to hyperoxia (FiO2 = 80 %) for 7 days to induce lung injury and fibrosis. The therapeutic effects of bLF, administered via an aerosol delivery system, on the chronic lung injury induced by this period of hyperoxia were measured by bronchoalveolar lavage, lung histology, cell apoptosis, and inflammatory cytokines in the lung tissues. After exposure to hyperoxia for 7 days, the survival of the mice was significantly decreased to 20 %. The protective effects of bLF against hyperoxia were further confirmed by significant reductions in lung edema, total cell numbers in bronchoalveolar lavage fluid, inflammatory cytokines (IL-1β and IL-6), pulmonary fibrosis, and apoptotic DNA fragmentation. The aerosolized bLF protected the mice from oxygen toxicity and increased the survival fraction to 66.7 % in the hyperoxic model. The results support the use of an aerosol therapy with bLF in intensive care units to reduce oxidative injury in patients with severe hypoxemic respiratory failure or chronic obstructive pulmonary disease.
Department of Bioresources, Da-Yeh University, Changhwa, 515, Taiwan.
Hsiao-Ling
HL
Chen
Chih-Ching
CC
Yen
Shih-Ming
SM
Wang
Tung-Chou
TC
Tsai
Zi-Lun
ZL
Lai
Jheng-Yue
JY
Sun
Willei
W
Lin
Wu-Huei
WH
Hsu
Chuan-Mu
CM
Chen
D000280:Administration, Inhalation; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002417:Cattle; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D018496:Hyperoxia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D007155:Immunologic Factors / Q000008:administration & dosage; D007249:Inflammation / Q000473:pathology / Q000517:prevention & control; D007781:Lactoferrin / Q000008:administration & dosage*; D055370:Lung Injury / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008813:Mice, Inbred ICR; D011658:Pulmonary Fibrosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control
D016207:Cytokines; D007155:Immunologic Factors; D007781:Lactoferrin